Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 351

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT 1B/1D Agonists) in the Acute Treatment of Migraine

Dodick, David, Lipton, Richard B., Martin, Vincent, Papademetriou, Vasilios, Rosamond, Wayne, MaassenVanDenBrink, Antoinette, Loutfi, Hassan, Welch, K.Michael, Goadsby, Peter J., Hahn, Steven, Hutchinson, Susan, Matchar, David, Silberstein, Stephen, Smith, Timothy R., Purdy, R. Allan, Saiers, Jane, The Triptan Cardiovascular Safety Expert Panel·2004·Headache: The Journal of Head and Face Pain

Abstract

Background.—Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan‐associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine. Objective.—To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice. Participants.—The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology. Evidence and Consensus Process.—An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow‐up meetings were held by telephone. Conclusions.—(1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk‐benefit profile of triptans favors their use in the absence of contraindications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1526-4610.2004.04078.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 351

Metadata

Authors
Dodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., MaassenVanDenBrink, A., Loutfi, H., Welch, K. M., Goadsby, P. J., Hahn, S., Hutchinson, S., Matchar, D., Silberstein, S., Smith, T. R., Purdy, R. A., Saiers, J., & Panel, T. T. C. S. E.
Venue
Headache: The Journal of Head and Face Pain
Publisher
Wiley
Published
2004-05-07
Volume
44
Issue
5
Pages
414-425
ISSN
  • 0017-8748 (ISSN-L)
  • 1526-4610
OpenAlex
W1983153788
Cited by
351
References
1
FWCI
11.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT 1B/1D Agonists) in the Acute Treatment of Migraine. https://app.cochat.ai/papers/10.1111/j.1526-4610.2004.04078.x
The paper
Dodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., MaassenVanDenBrink, A., Loutfi, H., Welch, K. M., Goadsby, P. J., Hahn, S., Hutchinson, S., Matchar, D., Silberstein, S., Smith, T. R., Purdy, R. A., Saiers, J., & Panel, T. T. C. S. E. (2004). Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT 1B/1D Agonists) in the Acute Treatment of Migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2004.04078.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.